A Phase 3, Multi-Center, Open-label Study to Test the Diagnostic Performance of Copper Cu 64 PSMA I&T PET/CT in Men With Biochemical Recurrence of Prostate Cancer
Latest Information Update: 22 Nov 2024
Price :
$35 *
At a glance
- Drugs Cu 64 PSMA I and T Curium Pharma (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Diagnostic use; Registrational
- Acronyms Solar-Recur
- Sponsors Curium Pharma
- 18 Nov 2024 Status changed from recruiting to active, no longer recruiting.
- 23 Apr 2024 Status changed from not yet recruiting to recruiting.
- 23 Apr 2024 According to Curium media release, company announced that it has successfully enrolled and scanned patients at sites across the U.S. and will be opening clinical trial sites in Europe later this year.